Previous studies in breast cancer highlighted that PTPRZ1 was a risk factor for poor prognosis in TNBC and found that PTN-PTPRZ1 was driven by chemotherapy, indicating its role in chemoresistance [14] that gives rise to disease recurrence. This evidence concerns the gene PTPRZ1 and breast carcinoma.